Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 2/20 | 0.42 |
| ▸ | NOS1 | P29475 | 2/20 | 0.42 |
| ▸ | NOS2 | P35228 | 2/20 | 0.42 |
| ▸ | OTC | P00480 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.34 |
| ▸ | P2RY10 | O00398 | 2/20 | 0.33 |
| ▸ | GPR174 | Q9BXC1 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | ALB | P02768 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HPSE | Q9Y251 | 2/20 | 0.31 |
| ▸ | TLR2 | O60603 | 2/20 | 0.31 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.31 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16446881 | 0.83 | NOS3 (0.44) | NOS3NOS1NOS2 | |
| SCHEMBL20192734 | 0.81 | NOS3 (0.41) | NOS3NOS1NOS2OTCSMN1; SMN2 | |
| SCHEMBL16447078 | 0.81 | NOS3 (0.43) | NOS3NOS1NOS2 | |
| SCHEMBL16447237 | 0.80 | NOD1 (0.49) | NOS3NOS1NOS2OTCNOD1 | |
| SCHEMBL24610028 | 0.79 | OTC (0.44) | NOS2OTCNOD1TSHRDDAH1 | |
| SCHEMBL15469244 | 0.79 | OTC (0.44) | NOS2OTCNOD1TSHRDDAH1 | |
| SCHEMBL31688850 | 0.79 | NOS2 (0.58) | NOS3NOS1NOS2P2RY10TSHR | |
| SCHEMBL20871341 | 0.79 | NOS2 (0.43) | NOS3NOS1NOS2OTCNOD1 | |
| SCHEMBL15469219 | 0.78 | NOS3 (0.38) | NOS3NOS1NOS2OTCDDAH1 | |
| SCHEMBL16447245 | 0.77 | NOS2 (0.46) | NOS3NOS1NOS2OTCNOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3030545-B1 | AMINO ACID DERIVATIVES | MEDIMMUNE LTD (GB) | 2020-10-07 | — | — | EP | disclosed |
| US-9981908-B2 | Amino acid derivatives | MEDIMMUNE LIMITED (GB) | 2018-05-29 | — | — | US | disclosed |
| US-9981908-B2 | Amino acid derivatives | MEDIMMUNE LIMITED (GB) | 2018-05-29 | — | — | US | disclosed |
| US-20160176811-A1 | Amino Acid Derivatives | ALLOZYNE, INC. | 2016-06-23 | — | — | US | disclosed |
| US-20160176811-A1 | Amino Acid Derivatives | ALLOZYNE, INC. | 2016-06-23 | — | — | US | disclosed |
| EP-3030545-A2 | AMINO ACID DERIVATIVES | Medimmune Limited (GB) | 2016-06-15 | — | — | EP | disclosed |
| WO-2015019192-A2 | AMINO ACID DERIVATIVES | MEDIMMUNE LIMITED (GB) | 2015-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160176811-A1 | Amino Acid Derivatives | BCAT2, BCAT1, DAO | NOS3 2449/4885NOS1 3381/4885NOS2 3197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.